Screener / SEC EDGAR /CIK 0000882095 /10-K filed Feb 24, 2026, compared with Feb 28, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Biotechnology

Gilead Sciences GILD

Compare with peers Embed
Earnings releases

Latest results release: Oct 29, 2026

8-K item 2.02, exhibit 99

What GILD's management wrote with each quarter's results: the press release and, when the company files them, its prepared remarks or the call transcript. The call itself is not filed with SEC, so most quarters have the release only.

Adjusted vs GAAP earnings per share

In the company's own words · read from each release, never computed

In its release of Aug 4, 2026, GILD reported −$8.45 per share under GAAP and −$6.75 on its own adjusted basis.

GAAP EPS $1.73, release Nov 7, 2023: Diluted Earnings Per Share (“EPS”) increased to $1.73 for the third quarter of 2023 compared to $1.42 for the same period in 2022, and non-GAAP diluted EPS increased to $2.29 for the third quarter of 2023 compared to $1.90 for the same period in 2022. Adjusted EPS $2.29, release Nov 7, 2023: Diluted Earnings Per Share (“EPS”) increased to $1.73 for the third quarter of 2023 compared to $1.42 for the same period in 2022, and non-GAAP diluted EPS increased to $2.29 for the third quarter of 2023 compared to $1.90 for the same period in 2022. +32% 2023-11 GAAP EPS $1.14, release Feb 6, 2024: Diluted Earnings Per Share (“EPS”) decreased to $1.14 in the fourth quarter 2023 compared to Adjusted EPS $1.72, release Feb 6, 2024: Non-GAAP diluted EPS increased to $1.72 in the fourth quarter 2023 compared to $1.67 in the same period in 2022, primarily due to lower total costs and expenses, partially offset by lower Veklury revenues. +51% 2024-02 GAAP EPS $-8.45, release Aug 4, 2026: Veklury Increased 10% Year-Over-Year to $7.6 billion Biktarvy Sales Increased 7% Year-Over-Year to $3.8 billion Diluted Loss Per Share was $(8.45) and Non-GAAP Diluted Loss Per Share was Adjusted EPS $-6.75, release Aug 4, 2026: billion Biktarvy Sales Increased 7% Year-Over-Year to $3.8 billion Diluted Loss Per Share was $(8.45) and Non-GAAP Diluted Loss Per Share was $(6.75) Reflecting $(9.08) Per Share Acquired I 2026-08
GAAP EPSAdjusted EPS, as the company defines itThe figure on top is how far adjusted is from GAAP. Click a bar for the sentence.
ReleaseGAAP EPSAdjusted EPSGap
Aug 4, 2026 -8.45 -6.75 –
Feb 6, 2024 1.14 1.72 +51%
Nov 7, 2023 1.73 2.29 +32%
The company's words, latest release
Veklury Increased 10% Year-Over-Year to $7.6 billion Biktarvy Sales Increased 7% Year-Over-Year to $3.8 billion Diluted Loss Per Share was $(8.45) and Non-GAAP Diluted Loss Per Share was release
billion Biktarvy Sales Increased 7% Year-Over-Year to $3.8 billion Diluted Loss Per Share was $(8.45) and Non-GAAP Diluted Loss Per Share was $(6.75) Reflecting $(9.08) Per Share Acquired I release

Both numbers are read from the words of each release (usually the highlights), never computed by us; hover a number for its sentence. Quarters where the release gives them only in a table are not shown. The company decides what "adjusted" leaves out; the full reconciliation is in the release.

Read and search

Every release, in full · linked to sec.gov

Press release Oct 29, 2026 · EX-99.1

GILEAD SCIENCES ANNOUNCES THIRD QUARTER 2026 FINANCIAL RESULTS

Open on SEC

- Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the third quarter 2026.

“Gilead delivered an exceptional third quarter, with our strongest year-over- year base business growth in more than a decade, reflecting the strength, breadth and durability of our business,” said Daniel O’Day, Gilead’s Chairman and Chief Executive Officer. “Our performance enabled us to raise our full year base business revenue guidance again this quarter, bringing the total increase to $1.6 billion since the start of 2026. Our HIV business grew 18% and HIV prevention sales nearly doubled year-over-year. With multiple ongoing and potential launches across HIV and Oncology, important progress in Inflammation and a disciplined operating model, Gilead is well positioned for business growth and impact for patients.”

• Total third quarter 2026 product sales increased 13% to $8.3 billion compared to the same period in 2025, primarily driven by higher sales of HIV products, Trodelvy® (sacituzumab govitecan-hziy) and Livdelzi® (seladelpar), partially offset by lower sales of Veklury® (remdesivir) and Cell Therapy products. Higher product sales were partially offset by lower royalty, contract and other revenues, primarily driven by revenues recognized in the prior year related to a previous sale of intellectual property, which did not repeat in the current year.

• Diluted earnings per share (“EPS”) was $1.94 in the third quarter 2026 compared to $2.43 in the same period in 2025. The decrease was primarily driven by net losses from equity securities in the current year compared to net gains in the prior year, higher operating expenses, higher income tax expense and lower royalty, contract and other revenues, partially offset by higher product sales and lower acquired in-process research and development (“IPR&D”) expenses.

• Non-GAAP diluted EPS was $2.55 in the third quarter 2026 compared to $2.47 in the same period in 2025. The increase was primarily driven by higher product sales and lower acquired IPR&D expenses, partially offset by higher operating expenses, higher income tax expense and lower royalty, contract and other revenues.

• As of September 30, 2026, Gilead had $6.4 billion of cash, cash equivalents and marketable debt securities compared to $10.6 billion as of December 31, 2025. The decrease was primarily driven by year-to-date cash outflows of $11.3 billion related to acquisitions, $2.8 billion of debt repayments, $3.1 billion of dividend payments and $1.1 billion of common stock repurchases, partially offset by $11.2 billion of operating cash flow and $4.1 billion of net proceeds from debt financing.

• During the third quarter 2026, Gilead generated $5.0 billion in operating cash flow.

• During the third quarter 2026, Gilead paid dividends of $1.0 billion and repurchased $370 million of common stock.

As noted in the section above, total third quarter 2026 product sales increased compared to the same period in 2025. Total third quarter 2026 product sales excluding Veklury increased 16% to $8.2 billion compared to the same period in 2025, primarily due to higher sales of HIV products, Trodelvy and Livdelzi, partially offset by lower sales of Cell Therapy products.

product sales increased 18% to $6.2 billion in the third quarter 2026 compared to the same period in 2025, primarilydriven by higher average realized price, higher demand in HIV prevention and favorable inventory dynamics.

(bictegravir 50mg/emtricitabine (“FTC”) 200mg/tenofovir alafenamide (“TAF”) 25mg) sales increased 10% to $4.1 billion in the third quarter 2026 compared to the same period in 2025, primarily driven by higher demand, higher average realized price and favorable inventory dynamics.

(FTC 200mg/TAF 25mg) sales increased 49% to $1.0 billion in the third quarter 2026 compared to the same period in 2025, primarily driven by higher average realized price and favorable inventory dynamics.

portfolio sales increased 13% to $927 million in the third quarter 2026 compared to the same period in 2025, primarily reflecting higher demand for Livdelzi, as well as higher average realized price for chronic hepatitis C virus (“HCV”) and chronic hepatitis B virus products, partially offset by lower demand for HCV products.

sales decreased 69% to $86 million in the third quarter 2026 compared to the same period in 2025, primarily driven by lower rates of COVID-19-related hospitalizations.

product sales decreased 18% to $355 million in the third quarter 2026 compared to the same period in 2025, reflecting ongoing competitive headwinds.

(sacituzumab govitecan-hziy) sales increased 42% to $506 million in the third quarter 2026 compared to the same period in 2025, primarily driven by higher demand.

Third Quarter 2026 Product Gross Margin, Operating Expenses and Effective Tax Rate

• Product gross margin was 81.0% in the third quarter 2026 compared to 78.6% in the same period in 2025. Non-GAAP product gross margin was 88.1% in the third quarter 2026 compared to 86.5% in the same period in 2025. These increases were primarily driven by the expiration of a royalty-related obligation.

• Research and development (“R&D”) expenses and non-GAAP R&D expenses increased to $1.6 billion in the third quarter 2026 compared to $1.3 billion in the same period in 2025, primarily driven by higher employee-related and clinical materials costs.

• Selling, general and administrative (“SG&A”) expenses increased to $1.6 billion in the third quarter 2026 compared to $1.4 billion in the same period in 2025, primarily driven by higher HIV promotional activities, integration costs related to our recent acquisitions, higher expenses related to legal matters and higher employee-related costs. Non-GAAP SG&A expenses increased to $1.5 billion in the third quarter 2026 compared to $1.4 billion in the same period in 2025, primarily due to higher HIV promotional activities, higher expenses related to legal matters and higher employee-related costs.

• The effective tax rate (“ETR”) was 20.7% in the third quarter 2026 compared to 16.2% in the same period in 2025, primarily driven by a settlement with a tax authority and remeasurement of certain deferred tax liabilities in the prior year, which did not repeat in the current year. The non-GAAP ETR was 19.0% in the third quarter 2026 compared to 17.5% in the same period in 2025, primarily due to the settlement with a tax authority in the prior year.

Our full year 2026 GAAP and non-GAAP diluted loss per share guidance includes the impact of approximately $9.88 due to acquired IPR&D charges of $12.4 billion related to the Arcellx, Tubulis, Ouro Medicines and PepStar transactions announced this year, net of the impact of the Lakefront collaboration and related taxes.

Additional information and a reconciliation between GAAP and non-GAAP financial information for the 2026 guidance is provided in the accompanying tables. The financial guidance is subject to a number of risks and uncertainties. See the Forward-Looking Statements section below.

• Received U.S. Food and Drug Administration (“FDA”) approval for Bixlenvo™ (bictegravir 75 mg/lenacapavir 50 mg) for the treatment of HIV in adults who are virologically suppressed on a stable antiretroviral regimen, including those switching from complex multi-tablet regimens. Bixlenvo is a complete single- tablet regimen indicated for the treatment of HIV to replace current antiretroviral regimens in people with virological suppression with no known or suspected resistance to bictegravir or lenacapavir.

• Announced the expansion of the six royalty-free voluntary licensing agreements for twice-yearly lenacapavir to include the investigational once-yearly lenacapavir for HIV prevention, if approved. This agreement covers 120 high- incidence countries and will support manufacturing readiness, technology transfer and future supply while the Phase 3 PURPOSE-365 trial is ongoing. If approved, once-yearly lenacapavir could provide a full year of HIV prevention with a single annual dose, expanding prevention choice and helping address barriers that can limit HIV pre-exposure prophylaxis (“PrEP”) uptake and persistence.

• Announced a new agreement with the Pan American Health Organization (“PAHO”) to accelerate access for twice-yearly lenacapavir for HIV prevention across all PAHO Member States in Latin America and the Caribbean. This agreement is part of Gilead’s broader global access strategy for lenacapavir which combines voluntary licensing, technology transfer, no-profit supply, regional access pathways and partnerships in providing access to HIV prevention.

• Announced European Commission (“EC”) marketing authorization for Trodelvy in combination with Keytruda® (pembrolizumab) for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (“mTNBC”) who have not received prior systemic therapy for metastatic disease and whose tumors express PD-L1 (CPS≥10). This decision follows the recent EC approval of Trodelvy as a monotherapy for the treatment of adults with unresectable locally advanced or mTNBC who have not received prior systemic therapy for metastatic disease and are not candidates for PD-(L)1 inhibitors. Trodelvy is now the only approved Trop-2 directed ADC and backbone therapy for 1L mTNBC across PD-L1 status.

• Announced a definitive agreement with PepStar Therapeutics Limited (“PepStar”), a privately held, clinical-stage biotechnology company, to acquire PepStar’s oral IL-23R inhibitor program. This includes lead asset HCXT-2001, an investigational, oral, macrocyclic peptide inhibitor of IL-23R, currently in Phase 1 development for immune-mediated inflammatory diseases. Closing of the transaction is subject to certain customary conditions.

• Presented new positive results from the Phase 2 SWIFT study evaluating emvistegrast, a once-daily oral alpha-4-beta-7 inhibitor, in adults with moderately-to-severely active ulcerative colitis (“UC”) at the United European Gastroenterology Week. Emvistegrast 200mg met its primary endpoint of clinical response at Week 12, with a generally well-tolerated safety profile. These findings support Gilead’s plans to initiate a Phase 3 study of emvistegrast 200mg as a monotherapy for UC in 2027. Emvistegrast is an investigational product that is not approved anywhere globally, and the safety and efficacy of its use is not yet established.

• Announced opening of new Research Center to expand capabilities in oncology, inflammation and research data science. The Research Center is the first of three projects supporting the $32 billion investment in U.S. research, development and manufacturing through 2030.

• In October 2026, the Centers for Medicare and Medicaid Services completed the process of setting the Maximum Fair Price for Biktarvy under Medicare. The new price will be effective and impact our Biktarvy revenue starting January 1, 2028.

• The Board declared a quarterly dividend of $0.82 per share of common stock for the fourth quarter of 2026. The dividend is payable on December 30, 2026, to stockholders of record at the close of business on December 15, 2026. Future dividends will be subject to Board approval.

Certain amounts and percentages in this press release may not sum or recalculate due to rounding.

At 1:30 p.m. Pacific Time today, Gilead will host a conference call to discuss Gilead’s results. A live webcast will be available on http://investors.gilead.com and will be archived on www.gilead.com for one year.

The information presented in this document has been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”), unless otherwise noted as non-GAAP. Management believes non-GAAP information is useful for investors, when considered in conjunction with Gilead’s GAAP financial information, because management uses such information internally for its operating, budgeting and financial planning purposes. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of Gilead’s operating results as reported under GAAP. Non-GAAP financial information generally excludes acquisition-related expenses including amortization of acquired intangible assets, restructuring charges and other items that are considered unusual or not representative of underlying trends of Gilead’s business, fair value adjustments of equity securities, the related tax charges or benefits associated with such exclusions and other discrete tax charges or benefits not representative of underlying trends such as changes in tax laws, transfers of intangible assets between certain legal entities, and effects of legal entity restructurings. Although Gilead consistently excludes the amortization of acquired intangible assets from the non-GAAP financial information, management believes that it is important for investors to understand that such intangible assets were recorded as part of acquisitions and contribute to ongoing revenue generation. Non-GAAP measures may be defined and calculated differently by other companies in the same industry. Reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures are provided in the accompanying tables.

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

Statements included in this press release that are not historical in nature are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Gilead cautions readers that forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include those relating to: Gilead’s ability to achieve its full year 2026 financial guidance and future projected financial results; impacts resulting from regulatory or legislative policies or processes, including the impact from pricing reform in the Inflation Reduction Act (such as Medicare Part D pricing reform and the Biktarvy Maximum Fair Price determination), the expiration of subsidies related to the Affordable Care Act, our most-favored-nation pricing agreement with the U.S. government and tariffs; Gilead’s ability to make progress on any of its long-term ambitions or priorities laid out in its corporate strategy; Gilead’s ability to accelerate or sustain revenues for its virology, oncology, inflammation and other programs; Gilead’s ability to manage, execute and realize the potential benefits of acquisitions, collaborations or licensing arrangements, including the announced PepStar acquisition; the risk that Gilead’s U.S. manufacturing and R&D investment may not achieve their intended benefits; patent protection and estimated loss of exclusivity for our products and product candidates; Gilead’s ability to initiate, progress or complete clinical trials within currently anticipated timeframes or at all, the possibility of unfavorable results from ongoing and additional clinical trials, including those involving anito-cel, emvistegrast, lenacapavir and HCXT-2001 (such as PURPOSE-365 and SWIFT), and the risk that safety and efficacy data from clinical trials may not warrant further development of Gilead’s product candidates or the product candidates of Gilead’s strategic partners; Gilead’s ability to resolve the issues cited by the FDA in pending clinical holds to the satisfaction of the FDA and the risk that FDA may not remove such clinical holds, in whole or in part, in a timely manner or at all; Gilead’s ability to submit new drug applications for new product candidates or expanded indications in the currently anticipated timelines; Gilead’s ability to receive or maintain regulatory approvals in a timely manner or at all, and the risk that any such approvals, if granted, may be subject to significant limitations on use and may be subject to withdrawal or other adverse actions by the applicable regulatory authority; Gilead’s ability to successfully commercialize its products; the risk of potential disruptions to the manufacturing and supply chain of Gilead’s products; pricing and reimbursement pressures from government agencies and other third parties, including required rebates and other discounts; a larger than anticipated shift in payer mix to more highly discounted payer segments; market share and price erosion caused by the introduction of generic versions of Gilead products; the risk that physicians and patients may not see advantages of Gilead’s products over other therapies, including Bixlenvo and Trodelvy; Gilead’s ability to effectively manage, execute and realize the anticipated benefits of the access strategy relating to lenacapavir for HIV PrEP, including voluntary licensing arrangements and external partnerships relating to lenacapavir; and other risks identified from time to time in Gilead’s reports filed with the SEC, including annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. In addition, Gilead makes estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures. Gilead bases its estimates on historical experience and on various other market specific and other relevant assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. There may be other factors of which Gilead is not currently aware that may affect matters discussed in the forward-looking statements and may also cause actual results to differ significantly from these estimates. Further, results for the quarter ended September 30, 2026 are not necessarily indicative of operating results for any future periods. Gilead directs readers to its press releases, annual reports on Form 10-K, quarterly reports on Form 10-Q and other subsequent disclosure documents filed with the SEC. Gilead claims the protection of the Safe Harbor contained in the Private Securities Litigation

The reader is cautioned that forward-looking statements are not guarantees of future performance and is cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to Gilead and Gilead assumes no obligation to update or supplement any such forward-looking statements other than as required by law. Any forward-looking statements speak only as of the date hereof or as of the dates indicated in the statements.

Additional information is available on our Investor Relations website, https://investors.gilead.com. Among other things, an estimate of Acquired IPR&D expenses is expected to be made available on the Quarterly Results page within the first ten (10) days after the end of each quarter. # # # G ilead owns or has rights to various trademarks, copyrights and trade names used in its business, including the following: GILEAD®, GILEAD SCIENCES®, KITE®, AMBISOME®, ATRIPLA®, BIXLENVO ™ , BIKTARVY®, CAYSTON®, COMPLERA®, DESCOVY®, DESCOVY FOR PREP®, EMTRIVA®, EPCLUSA®, EVIPLERA®, GENVOYA®, HARVONI®, HEPCLUDEX®, JYSELECA®, LIVDELZI®/LYVDELZI®, LETAIRIS®, ODEFSEY®, SOVALDI®, STRIBILD®, SUNLENCA®, TECARTUS®, TRODELVY®, TRUVADA®, TRUVADA FOR PREP®, TYBOST®, VEKLURY®, VEMLIDY®, VIREAD®, VOSEVI®, YESCARTA®, YEZTUGO®/YEYTUO® and ZYDELIG®. Other trademarks and trade names are the property of their respective owners. For more information on Gilead Sciences, Inc., please visit www.gilead.com or call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235).

CONTACTS: Investors: Jacquie Ross, CFA [email protected]… Media: Ashleigh Koss [email protected]

(1) Refer to Non-GAAP Financial Information section above for further disclosures on non-GAAP financial measures. A reconciliation between GAAP and non-GAAP financial information is provided in the tables below.

(in million… except percent… and per Three Nine share Months Months amounts) Ended Ended Non-GAAP September September adjustm… 30, 30, summary: 2026 2025 2026 2025 ────────────────────────────────────────────────────────────────────────────── Cost of goods $ 588 $ 577 $ 1,744 $ 1,735 sold adjustm… Research and develop… 16 12 369 93 expenses adjustm… IPR&D impairm… — — 1,750 190 adjustm… Selling, general and 102 5 590 49 adminis… expenses adjustm… Total non-GAAP adjustm… 706 594 4,453 2,067 to costs and expenses Other (income) expense, 164 -483 -321 -198 net, adjustm… Total non-GAAP adjustm… 870 112 4,132 1,868 before income taxes Income tax effect of -175 -79 -807 -396 non-GAAP adjustm… above Discrete and related 62 11 64 101 tax charges… Total non-GAAP adjustm… $ 757 $ 43 $ 3,389 $ 1,573 to net income

(2) Adjustments include integration expenses and contingent consideration fair value adjustments associated with Gilead’s recent acquisitions.

(3) Adjustments include donations of equity securities to the Gilead Foundation, a California nonprofit organization, during the first quarter of 2026.

(4) Represents discrete and related deferred tax charges or benefits primarily associated with acquisition-related adjustments and transfers of intangible assets from a foreign subsidiary to Ireland and the United States.

(in millions, except percentages and per Provided Updated May Updated Updated share February 10, 7, August 4, October amounts) 2026 2026 2026 29, 2026 ────────────────────────────────────────────────────────────────────────────── Projected product gross margin GAAP to non-GAAP reconcilia… GAAP projected product ~ 79.0% ~ 79.0% ~ 79.0% ~ 79.0% gross margin Acquisitio… ~ 8.0% ~ 8.0% ~ 8.0% ~ 8.0% expenses Non-GAAP projected product ~ 87.0% ~ 87.0% ~ 87.0% ~ 87.0% gross margin Projected operating income (loss) GAAP to non-GAAP reconcilia… GAAP projected $11,400 - $(1,000) - $(2,250) - $(3,150) - operating $11,900 $(500) $(1,850) $(2,750) income (loss) Acquisitio… IPR&D impairment, ~ 2,400 ~ 3,400 ~ 5,150 ~ 5,150 restructur… and other expenses Non-GAAP projected $13,800 - $2,400 - $2,900 - $2,000 - operating $14,300 $2,900 $3,300 $2,400 income Projected effective tax rate GAAP to non-GAAP reconcilia… GAAP projected ~ 21% ~ (150%) - ~ (80%) - ~ (50%) - effective (220%) (90%) (55%) tax rate Income tax effect of above non-GAAP adjustments and fair value adjustments -~ 1% NM NM NM of equity securities, and discrete and related tax adjustments Non-GAAP projected ~ 20% ~ 190% - ~ 140% - 115% ~ 220% - effective 140% 165% tax rate Projected diluted earnings (loss) per share GAAP to non-GAAP reconcilia… GAAP projected diluted $6.75 - $(3.25) - $(3.75) - $(4.40) - earnings $7.15 $(2.85) $(3.40) $(4.05) (loss) per share Acquisitio… IPR&D impairment, restructur… and other expenses, fair value ~ 1.70 ~ 2.20 ~ 3.10 ~ 3.20 adjustments of equity securities and discrete and related tax adjustments Non-GAAP projected diluted $8.45 - $(1.05) - $(0.65) - $(1.20) - earnings $8.85 $(0.65) $(0.30) $(0.85) (loss) per share

(1) Our full-year guidance excludes the potential impact of any (i) acquisitions or business development transactions that have not been executed, (ii) future fair value adjustments of equity securities and (iii) discrete tax charges or benefits associated with changes in tax related laws and guidelines that have not been enacted, as Gilead is unable to project such amounts. The non-GAAP full-year guidance includes non-GAAP adjustments to actual current period results as well as adjustments for the known future impact associated with events that have already occurred, such as future amortization of our intangible assets and the future impact of discrete and related deferred tax charges or benefits primarily associated with transfers of intangible assets from a foreign subsidiary to Ireland and the United States.

(2) The GAAP and non-GAAP projected effective tax rates for the October 29, 2026 update include the impact of Acquired IPR&D expenses related to the acquisitions of Arcellx, Tubulis and Ouro Medicines, which are not deductible for tax purposes. Without these Acquired IPR&D expenses, the GAAP and non-GAAP projected effective tax rate for FY26 would be ~21% and ~20%, respectively.

(1) Includes current and long-term inventories, which are disclosed separately in the notes to our financial statements in Form 10-K and Form 10-Q.

(2) As of September 30, 2026 and December 31, 2025, there were 1,241 of shares of common stock issued and outstanding.

(1) Free cash flow is a non-GAAP liquidity measure. Please refer to our disclosures in the Non-GAAP Financial Information section above.

(1) Represents Gilead’s revenue from cobicistat (“C”), FTC and TAF in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company.

(2) Includes Atripla, Bixlenvo, Complera/Eviplera, Emtriva, Stribild, Sunlenca, Truvada and Tybost.

(3) Includes Epclusa and the authorized generic version of Epclusa sold by Gilead’s separate subsidiary, Asegua Therapeutics LLC (“Asegua”).

(4) Includes ledipasvir/sofosbuvir (Harvoni and the authorized generic version of Harvoni sold by Asegua), Hepcludex, Sovaldi, Viread and Vosevi.

Full text with the tables
                         
  October 29, 2026    1  
 ─────────────────────── 
                         
         GILEAD SCIENCES ANNOUNCES THIRD QUARTER 2026 FINANCIAL RESULTS         
                                                                                
  Product Sales Excluding Veklury Increased 16% Year-Over-Year to $8.2 Billion  
                                                                                
          Biktarvy Sales Increased 10% Year-Over-Year to $4.1 Billion           
                                                                                
  Foster City, CA, October 29, 2026                                             
                                                                                
- Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations
for the third quarter 2026.

“Gilead delivered an exceptional third quarter, with our strongest year-over-
year base business growth in more than a decade, reflecting the strength,
breadth and durability of our business,” said Daniel O’Day, Gilead’s Chairman
and Chief Executive Officer. “Our performance enabled us to raise our full year
base business revenue guidance again this quarter, bringing the total increase
to $1.6 billion since the start of 2026. Our HIV business grew 18% and HIV
prevention sales nearly doubled year-over-year. With multiple ongoing and
potential launches across HIV and Oncology, important progress in Inflammation
and a disciplined operating model, Gilead is well positioned for business growth
and impact for patients.”
                                                                                
   Third Quarter 2026 Financial Results                                         
                                                                                
• Total third quarter 2026 product sales increased 13% to $8.3 billion compared
to the same period in 2025, primarily driven by higher sales of HIV products,
Trodelvy® (sacituzumab govitecan-hziy) and Livdelzi® (seladelpar), partially
offset by lower sales of Veklury® (remdesivir) and Cell Therapy products. Higher
product sales were partially offset by lower royalty, contract and other
revenues, primarily driven by revenues recognized in the prior year related to a
previous sale of intellectual property, which did not repeat in the current
year.

• Diluted earnings per share (“EPS”) was $1.94 in the third quarter 2026
compared to $2.43 in the same period in 2025. The decrease was primarily driven
by net losses from equity securities in the current year compared to net gains
in the prior year, higher operating expenses, higher income tax expense and
lower royalty, contract and other revenues, partially offset by higher product
sales and lower acquired in-process research and development (“IPR&D”) expenses.

• Non-GAAP diluted EPS was $2.55 in the third quarter 2026 compared to $2.47 in
the same period in 2025. The increase was primarily driven by higher product
sales and lower acquired IPR&D expenses, partially offset by higher operating
expenses, higher income tax expense and lower royalty, contract and other
revenues.

• As of September 30, 2026, Gilead had $6.4 billion of cash, cash equivalents
and marketable debt securities compared to $10.6 billion as of December 31,
2025. The decrease was primarily driven by year-to-date cash outflows of $11.3
billion related to acquisitions, $2.8 billion of debt repayments, $3.1 billion
of dividend payments and $1.1 billion of common stock repurchases, partially
offset by $11.2 billion of operating cash flow and $4.1 billion of net proceeds
from debt financing.

• During the third quarter 2026, Gilead generated $5.0 billion in operating cash
flow.

• During the third quarter 2026, Gilead paid dividends of $1.0 billion and
repurchased $370 million of common stock.
                         
  October 29, 2026    2  
 ─────────────────────── 
                         
                                                                                
  Third Quarter 2026 Product Sales                                              
                                                                                
As noted in the section above, total third quarter 2026 product sales increased
compared to the same period in 2025. Total third quarter 2026 product sales
excluding Veklury increased 16% to $8.2 billion compared to the same period in
2025, primarily due to higher sales of HIV products, Trodelvy and Livdelzi,
partially offset by lower sales of Cell Therapy products.
                                                                                
  HIV                                                                           
                                                                                
product sales increased 18% to $6.2 billion in the third quarter 2026 compared
to the same period in 2025, primarilydriven by higher average realized price,
higher demand in HIV prevention and favorable inventory dynamics.

•
                                                                                
  Biktarvy®                                                                     
                                                                                
(bictegravir 50mg/emtricitabine (“FTC”) 200mg/tenofovir alafenamide (“TAF”)
25mg) sales increased 10% to $4.1 billion in the third quarter 2026 compared to
the same period in 2025, primarily driven by higher demand, higher average
realized price and favorable inventory dynamics.

•
                                                                                
  Descovy®                                                                      
                                                                                
(FTC 200mg/TAF 25mg) sales increased 49% to $1.0 billion in the third quarter
2026 compared to the same period in 2025, primarily driven by higher average
realized price and favorable inventory dynamics.

The
                                                                                
  Liver Disease                                                                 
                                                                                
portfolio sales increased 13% to $927 million in the third quarter 2026 compared
to the same period in 2025, primarily reflecting higher demand for Livdelzi, as
well as higher average realized price for chronic hepatitis C virus (“HCV”) and
chronic hepatitis B virus products, partially offset by lower demand for HCV
products.
                                                                                
  Veklury                                                                       
                                                                                
sales decreased 69% to $86 million in the third quarter 2026 compared to the
same period in 2025, primarily driven by lower rates of COVID-19-related
hospitalizations.
                                                                                
  Cell Therapy                                                                  
                                                                                
product sales decreased 18% to $355 million in the third quarter 2026 compared
to the same period in 2025, reflecting ongoing competitive headwinds.
                                                                                
  Trodelvy®                                                                     
                                                                                
(sacituzumab govitecan-hziy) sales increased 42% to $506 million in the third
quarter 2026 compared to the same period in 2025, primarily driven by higher
demand.

Third Quarter 2026 Product Gross Margin, Operating Expenses and Effective Tax
Rate

• Product gross margin was 81.0% in the third quarter 2026 compared to 78.6% in
the same period in 2025. Non-GAAP product gross margin was 88.1% in the third
quarter 2026 compared to 86.5% in the same period in 2025. These increases were
primarily driven by the expiration of a royalty-related obligation.

• Research and development (“R&D”) expenses and non-GAAP R&D expenses increased
to $1.6 billion in the third quarter 2026 compared to $1.3 billion in the same
period in 2025, primarily driven by higher employee-related and clinical
materials costs.

• Acquired IPR&D expenses were $18 million in the third quarter 2026.

• Selling, general and administrative (“SG&A”) expenses increased to $1.6
billion in the third quarter 2026 compared to $1.4 billion in the same period in
2025, primarily driven by higher HIV promotional activities, integration costs
related to our recent acquisitions, higher expenses related to legal matters and
higher employee-related costs. Non-GAAP SG&A expenses increased to $1.5 billion
in the third quarter 2026 compared to $1.4 billion in the same period in 2025,
primarily due to higher HIV promotional activities, higher expenses related to
legal matters and higher employee-related costs.

• The effective tax rate (“ETR”) was 20.7% in the third quarter 2026 compared to
16.2% in the same period in 2025, primarily driven by a settlement with a tax
authority and remeasurement of certain deferred tax liabilities in the prior
year, which did not repeat in the current year. The non-GAAP ETR was 19.0% in
the third quarter 2026 compared to 17.5% in the same period in 2025, primarily
due to the settlement with a tax authority in the prior year.
                         
  October 29, 2026    3  
 ─────────────────────── 
                         
                                                                                
  Guidance and Outlook                                                          
                                                                                
For the full year 2026, Gilead now expects:
                                                                                
  (in                                                         Compa…            
  mill…                                                       to                
  exce…              Octob…                                   August            
  per                29,                                      4,                
  share    Low       2026              High                   2026              
  amou…    End       Guida…            End                    Guida…            
 ────────────────────────────────────────────────────────────────────────────── 
                                                                        Previ…  
  Prod…              $       31,000              $  31,300              $30,1…  
  sales                                                                 to      
                                                                        $30,4…  
  Prod…                                                                 Previ…  
  sales              $       30,700              $  31,000              $29,8…  
  excl…                                                                 to      
  Vekl…                                                                 $30,1…  
  Vekl…              ~ $300                                             Uncha…  
  Dilu…                                                                 Previ…  
  loss               $        -4.40              $   -4.05              $(3.7…  
  per                                                                   to      
  share                                                                 $(3.4…  
  Non-…                                                                 Previ…  
  dilu…                                                                 $(0.6…  
  loss               $        -1.20              $   -0.85              to      
  per                                                                   $(0.3…  
  share                                                                         
                                                                                
Our full year 2026 GAAP and non-GAAP diluted loss per share guidance includes
the impact of approximately $9.88 due to acquired IPR&D charges of $12.4 billion
related to the Arcellx, Tubulis, Ouro Medicines and PepStar transactions
announced this year, net of the impact of the Lakefront collaboration and
related taxes.

Additional information and a reconciliation between GAAP and non-GAAP financial
information for the 2026 guidance is provided in the accompanying tables. The
financial guidance is subject to a number of risks and uncertainties. See the
Forward-Looking Statements section below.
                                                                                
  Key Updates Since Our Last Quarterly Release                                  
                                                                                
                                                                                
  Virology                                                                      
                                                                                
• Received U.S. Food and Drug Administration (“FDA”) approval for Bixlenvo™
(bictegravir 75 mg/lenacapavir 50 mg) for the treatment of HIV in adults who are
virologically suppressed on a stable antiretroviral regimen, including those
switching from complex multi-tablet regimens. Bixlenvo is a complete single-
tablet regimen indicated for the treatment of HIV to replace current
antiretroviral regimens in people with virological suppression with no known or
suspected resistance to bictegravir or lenacapavir.

• Announced the expansion of the six royalty-free voluntary licensing agreements
for twice-yearly lenacapavir to include the investigational once-yearly
lenacapavir for HIV prevention, if approved. This agreement covers 120 high-
incidence countries and will support manufacturing readiness, technology
transfer and future supply while the Phase 3 PURPOSE-365 trial is ongoing. If
approved, once-yearly lenacapavir could provide a full year of HIV prevention
with a single annual dose, expanding prevention choice and helping address
barriers that can limit HIV pre-exposure prophylaxis (“PrEP”) uptake and
persistence.

• Announced a new agreement with the Pan American Health Organization (“PAHO”)
to accelerate access for twice-yearly lenacapavir for HIV prevention across all
PAHO Member States in Latin America and the Caribbean. This agreement is part of
Gilead’s broader global access strategy for lenacapavir which combines voluntary
licensing, technology transfer, no-profit supply, regional access pathways and
partnerships in providing access to HIV prevention.
                                                                                
  Oncology                                                                      
                                                                                
• Announced European Commission (“EC”) marketing authorization for Trodelvy in
combination with Keytruda® (pembrolizumab) for the treatment of adult patients
with unresectable locally advanced or metastatic triple-negative breast cancer
(“mTNBC”) who have not received prior systemic therapy for metastatic disease
and whose tumors express PD-L1 (CPS≥10). This decision follows the recent EC
approval of Trodelvy as a monotherapy for the treatment of adults with
unresectable locally advanced or mTNBC who have not received prior systemic
therapy for metastatic disease and are not candidates for PD-(L)1 inhibitors.
Trodelvy is now the only approved Trop-2 directed ADC and backbone therapy for
1L mTNBC across PD-L1 status.
                         
  October 29, 2026    4  
 ─────────────────────── 
                         
                                                                                
  Inflammation                                                                  
                                                                                
• Announced a definitive agreement with PepStar Therapeutics Limited
(“PepStar”), a privately held, clinical-stage biotechnology company, to acquire
PepStar’s oral IL-23R inhibitor program. This includes lead asset HCXT-2001, an
investigational, oral, macrocyclic peptide inhibitor of IL-23R, currently in
Phase 1 development for immune-mediated inflammatory diseases. Closing of the
transaction is subject to certain customary conditions.

• Presented new positive results from the Phase 2 SWIFT study evaluating
emvistegrast, a once-daily oral alpha-4-beta-7 inhibitor, in adults with
moderately-to-severely active ulcerative colitis (“UC”) at the United European
Gastroenterology Week. Emvistegrast 200mg met its primary endpoint of clinical
response at Week 12, with a generally well-tolerated safety profile. These
findings support Gilead’s plans to initiate a Phase 3 study of emvistegrast
200mg as a monotherapy for UC in 2027. Emvistegrast is an investigational
product that is not approved anywhere globally, and the safety and efficacy of
its use is not yet established.
                                                                                
  Corporate                                                                     
                                                                                
• Announced opening of new Research Center to expand capabilities in oncology,
inflammation and research data science. The Research Center is the first of
three projects supporting the $32 billion investment in U.S. research,
development and manufacturing through 2030.

• In October 2026, the Centers for Medicare and Medicaid Services completed the
process of setting the Maximum Fair Price for Biktarvy under Medicare. The new
price will be effective and impact our Biktarvy revenue starting January 1,
2028.

• The Board declared a quarterly dividend of $0.82 per share of common stock for
the fourth quarter of 2026. The dividend is payable on December 30, 2026, to
stockholders of record at the close of business on December 15, 2026. Future
dividends will be subject to Board approval.

Certain amounts and percentages in this press release may not sum or recalculate
due to rounding.
                                                                                
  Conference Call                                                               
                                                                                
At 1:30 p.m. Pacific Time today, Gilead will host a conference call to discuss
Gilead’s results. A live webcast will be available on
http://investors.gilead.com and will be archived on www.gilead.com for one year.
                                                                                
   Non-GAAP Financial Information                                               
                                                                                
The information presented in this document has been prepared in accordance with
U.S. generally accepted accounting principles (“GAAP”), unless otherwise noted
as non-GAAP. Management believes non-GAAP information is useful for investors,
when considered in conjunction with Gilead’s GAAP financial information, because
management uses such information internally for its operating, budgeting and
financial planning purposes. Non-GAAP information is not prepared under a
comprehensive set of accounting rules and should only be used to supplement an
understanding of Gilead’s operating results as reported under GAAP. Non-GAAP
financial information generally excludes acquisition-related expenses including
amortization of acquired intangible assets, restructuring charges and other
items that are considered unusual or not representative of underlying trends of
Gilead’s business, fair value adjustments of equity securities, the related tax
charges or benefits associated with such exclusions and other discrete tax
charges or benefits not representative of underlying trends such as changes in
tax laws, transfers of intangible assets between certain legal entities, and
effects of legal entity restructurings. Although Gilead consistently excludes
the amortization of acquired intangible assets from the non-GAAP financial
information, management believes that it is important for investors to
understand that such intangible assets were recorded as part of acquisitions and
contribute to ongoing revenue generation. Non-GAAP measures may be defined and
calculated differently by other companies in the same industry. Reconciliations
of the non-GAAP financial measures to the most directly comparable GAAP
financial measures are provided in the accompanying tables.
                         
  October 29, 2026    5  
 ─────────────────────── 
                         
                                                                                
  About Gilead Sciences                                                         
                                                                                
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and
achieved breakthroughs in medicine for more than three decades, with the goal of
creating a healthier world for all people. The company is committed to advancing
innovative medicines to prevent and treat life-threatening diseases, including
HIV, viral hepatitis, COVID-19, cancer and inflammation. Gilead operates in more
than 35 countries worldwide, with headquarters in Foster City, California.
                                                                                
  Forward-Looking Statements                                                    
                                                                                
Statements included in this press release that are not historical in nature are
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. Gilead cautions readers that forward-looking
statements are subject to certain risks and uncertainties that could cause
actual results to differ materially. These risks and uncertainties include those
relating to: Gilead’s ability to achieve its full year 2026 financial guidance
and future projected financial results; impacts resulting from regulatory or
legislative policies or processes, including the impact from pricing reform in
the Inflation Reduction Act (such as Medicare Part D pricing reform and the
Biktarvy Maximum Fair Price determination), the expiration of subsidies related
to the Affordable Care Act, our most-favored-nation pricing agreement with the
U.S. government and tariffs; Gilead’s ability to make progress on any of its
long-term ambitions or priorities laid out in its corporate strategy; Gilead’s
ability to accelerate or sustain revenues for its virology, oncology,
inflammation and other programs; Gilead’s ability to manage, execute and realize
the potential benefits of acquisitions, collaborations or licensing
arrangements, including the announced PepStar acquisition; the risk that
Gilead’s U.S. manufacturing and R&D investment may not achieve their intended
benefits; patent protection and estimated loss of exclusivity for our products
and product candidates; Gilead’s ability to initiate, progress or complete
clinical trials within currently anticipated timeframes or at all, the
possibility of unfavorable results from ongoing and additional clinical trials,
including those involving anito-cel, emvistegrast, lenacapavir and HCXT-2001
(such as PURPOSE-365 and SWIFT), and the risk that safety and efficacy data from
clinical trials may not warrant further development of Gilead’s product
candidates or the product candidates of Gilead’s strategic partners; Gilead’s
ability to resolve the issues cited by the FDA in pending clinical holds to the
satisfaction of the FDA and the risk that FDA may not remove such clinical
holds, in whole or in part, in a timely manner or at all; Gilead’s ability to
submit new drug applications for new product candidates or expanded indications
in the currently anticipated timelines; Gilead’s ability to receive or maintain
regulatory approvals in a timely manner or at all, and the risk that any such
approvals, if granted, may be subject to significant limitations on use and may
be subject to withdrawal or other adverse actions by the applicable regulatory
authority; Gilead’s ability to successfully commercialize its products; the risk
of potential disruptions to the manufacturing and supply chain of Gilead’s
products; pricing and reimbursement pressures from government agencies and other
third parties, including required rebates and other discounts; a larger than
anticipated shift in payer mix to more highly discounted payer segments; market
share and price erosion caused by the introduction of generic versions of Gilead
products; the risk that physicians and patients may not see advantages of
Gilead’s products over other therapies, including Bixlenvo and Trodelvy;
Gilead’s ability to effectively manage, execute and realize the anticipated
benefits of the access strategy relating to lenacapavir for HIV PrEP, including
voluntary licensing arrangements and external partnerships relating to
lenacapavir; and other risks identified from time to time in Gilead’s reports
filed with the SEC, including annual reports on Form 10-K, quarterly reports on
Form 10-Q and current reports on Form 8-K. In addition, Gilead makes estimates
and judgments that affect the reported amounts of assets, liabilities, revenues
and expenses and related disclosures. Gilead bases its estimates on historical
experience and on various other market specific and other relevant assumptions
that it believes to be reasonable under the circumstances, the results of which
form the basis for making judgments about the carrying values of assets and
liabilities that are not readily apparent from other sources. There may be other
factors of which Gilead is not currently aware that may affect matters discussed
in the forward-looking statements and may also cause actual results to differ
significantly from these estimates. Further, results for the quarter ended
September 30, 2026 are not necessarily indicative of operating results for any
future periods. Gilead directs readers to its press releases, annual reports on
Form 10-K, quarterly reports on Form 10-Q and other subsequent disclosure
documents filed with the SEC. Gilead claims the protection of the Safe Harbor
contained in the Private Securities Litigation
                         
  October 29, 2026    6  
 ─────────────────────── 
                         
Reform Act of 1995 for forward-looking statements.

The reader is cautioned that forward-looking statements are not guarantees of
future performance and is cautioned not to place undue reliance on these
forward-looking statements. All forward-looking statements are based on
information currently available to Gilead and Gilead assumes no obligation to
update or supplement any such forward-looking statements other than as required
by law. Any forward-looking statements speak only as of the date hereof or as of
the dates indicated in the statements.

Additional information is available on our Investor Relations website,
https://investors.gilead.com. Among other things, an estimate of Acquired IPR&D
expenses is expected to be made available on the Quarterly Results page within
the first ten (10) days after the end of each quarter.
                                     # # #                                      
G ilead owns or has rights to various trademarks, copyrights and trade names
used in its business, including the following: GILEAD®, GILEAD SCIENCES®, KITE®,
AMBISOME®, ATRIPLA®, BIXLENVO ™ , BIKTARVY®, CAYSTON®, COMPLERA®, DESCOVY®,
DESCOVY FOR PREP®, EMTRIVA®, EPCLUSA®, EVIPLERA®, GENVOYA®, HARVONI®,
HEPCLUDEX®, JYSELECA®, LIVDELZI®/LYVDELZI®, LETAIRIS®, ODEFSEY®, SOVALDI®,
STRIBILD®, SUNLENCA®, TECARTUS®, TRODELVY®, TRUVADA®, TRUVADA FOR PREP®,
TYBOST®, VEKLURY®, VEMLIDY®, VIREAD®, VOSEVI®, YESCARTA®, YEZTUGO®/YEYTUO® and
ZYDELIG®. Other trademarks and trade names are the property of their respective
owners.
 For more information on Gilead Sciences, Inc., please visit www.gilead.com or  
 call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235).  
                                                                                
  CONTACTS:    Investors:    Jacquie Ross, CFA    [email protected]…  
               Media:        Ashleigh Koss        [email protected]     
                                                                                
                         
  October 29, 2026    7  
 ─────────────────────── 
                         
                                                                                
                             GILEAD SCIENCES, INC.                              
                                                                                
                                                                                
                CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS                 
                                                                                
                                  (unaudited)                                   
                                                                                
  (in                                                                           
  mil…    Three                                Nine                             
  exc…    Mont…                                Mon…                             
  per     Ended                                End…                             
  sha…    Sept…                                Sep…                             
  amo…    30,                                  30,                              
  Rev…    2026               2025              2026              2025           
 ────────────────────────────────────────────────────────────────────────────── 
  Pro…    $      8,289       $     7,345       $     22,8…       $     21,…     
  sal…                                                                          
  Roy…                                                                          
  con…                                                                          
  and               11               424               201              505     
  oth…                                                                          
  rev…                                                                          
  Tot…           8,300             7,769             23,0…             21,…     
  rev…                                                                          
  Cos…                                                                          
  and                                                                           
  exp…                                                                          
  Cost                                                                          
  of             1,571             1,569             4,595             4,6…     
  goo…                                                                          
  sold                                                                          
  Res…                                                                          
  and            1,608             1,346             4,744             4,2…     
  dev…                                                                          
  exp…                                                                          
  Acq…                                                                          
  in-…                                                                          
  res…              18               170             11,3…              485     
  and                                                                           
  dev…                                                                          
  exp…                                                                          
  In-…                                                                          
  res…                                                                          
  and                —                 —             1,750              190     
  dev…                                                                          
  imp…                                                                          
  Sel…                                                                          
  gen…                                                                          
  and            1,641             1,357             5,013             3,9…     
  adm…                                                                          
  exp…                                                                          
  Tot…                                                                          
  cos…           4,838             4,442             27,4…             13,…     
  and                                                                           
  exp…                                                                          
  Ope…                                                                          
  inc…           3,462             3,327             -4,3…             8,0…     
  (lo…                                                                          
  Int…             269               256               756              769     
  exp…                                                                          
  Oth…                                                                          
  (in…             130              -569              -492             -449     
  exp…                                                                          
  net                                                                           
  Inc…                                                                          
  (lo…                                                                          
  bef…           3,063             3,641             -4,6…             7,7…     
  inc…                                                                          
  tax…                                                                          
  Inc…                                                                          
  tax              634               589             1,435             1,3…     
  exp…                                                                          
  Net                                                                           
  inc…    $      2,429       $     3,052       $     -6,0…       $     6,3…     
  (lo…                                                                          
  Bas…                                                                          
  ear…                                                                          
  (lo…    $       1.96       $      2.46       $     -4.87       $     5.08     
  per                                                                           
  sha…                                                                          
  Dil…                                                                          
  ear…                                                                          
  (lo…    $       1.94       $      2.43       $     -4.87       $     5.04     
  per                                                                           
  sha…                                                                          
  Sha…                                                                          
  used                                                                          
  in                                                                            
  bas…                                                                          
  ear…           1,242             1,243             1,242             1,2…     
  (lo…                                                                          
  per                                                                           
  sha…                                                                          
  cal…                                                                          
  Sha…                                                                          
  used                                                                          
  in                                                                            
  dil…                                                                          
  ear…           1,251             1,254             1,242             1,2…     
  (lo…                                                                          
  per                                                                           
  sha…                                                                          
  cal…                                                                          
  Sup…                                                                          
  Inf…                                                                          
  Cash                                                                          
  div…                                                                          
  dec…    $       0.82       $      0.79       $      2.46       $     2.37     
  per                                                                           
  sha…                                                                          
  Pro…                                                                          
  gro…            81.0  %           78.6  %           79.9  %          78.1  %  
  mar…                                                                          
  Res…                                                                          
  and                                                                           
  dev…                                                                          
  exp…            19.4  %           17.3  %           20.6  %          19.6  %  
  as a                                                                          
  %                                                                             
  of                                                                            
  rev…                                                                          
  Sel…                                                                          
  gen…                                                                          
  and                                                                           
  adm…            19.8  %           17.5  %           21.7  %          18.5  %  
  exp…                                                                          
  as a                                                                          
  % of                                                                          
  rev…                                                                          
  Ope…            41.7  %           42.8  %          -18.8  %          37.4  %  
  mar…                                                                          
  Eff…                                                                          
  tax             20.7  %           16.2  %          -31.1  %          18.0  %  
  rate                                                                          
                                                                                
                         
  October 29, 2026    8  
 ─────────────────────── 
                         
                                                                                
                             GILEAD SCIENCES, INC.                              
                                                                                
                                                                                
                             TOTAL REVENUE SUMMARY                              
                                                                                
                                  (unaudited)                                   
                                                                                
  (in    Thr…                                Nine                               
  mi…    Mon…                                Mon…                               
  ex…    End…                                End…                               
  pe…    Sep…                                Sep…                               
  Pr…    30,                                 30,                                
  sa…    2026          2025          Cha…    2026          2025           Cha…  
 ────────────────────────────────────────────────────────────────────────────── 
  HIV    $     6,2…    $     5,2…    18%     $     16,…    $     14,9…    14%   
  Li…           927           819    13%           2,5…          2,372    8%    
  Di…                                                                           
  On…           860           788    9%            2,5…          2,395    6%    
  Ot…           167           184    (9)%           524            594    (12…  
  To…                                                                           
  pr…                                                                           
  sa…          8,2…          7,0…    16%           22,…          20,3…    11%   
  ex…                                                                           
  Ve…                                                                           
  Ve…            86           277    (69…           253            700    (64…  
  To…                                                                           
  pr…          8,2…          7,3…    13%           22,…          21,0…    9%    
  sa…                                                                           
  Ro…                                                                           
  co…                                                                           
  and            11           424    (97…           201            505    (60…  
  ot…                                                                           
  re…                                                                           
  To…    $     8,3…    $     7,7…    7%      $     23,…    $     21,5…    7%    
  re…                                                                           
                                                                                
                         
  October 29, 2026    9  
 ─────────────────────── 
                         
                                                                                
                             GILEAD SCIENCES, INC.                              
                                                                                
                                                                                
                         NON-GAAP FINANCIAL INFORMATION                         
                                                                                
                                      (1)                                       
                                                                                
                                  (unaudited)                                   
                                                                                
        Th…                                  Ni…                                
  (…    Mo…                                  Mo…                                
  m…    En…                                  En…                                
  e…    Se…                                  Se…                                
  p…    30,                                  30,                                
  N…    20…            20…            Ch…    20…            20…            Ch…  
 ────────────────────────────────────────────────────────────────────────────── 
  C…                                                                            
  of    $    983       $    992       (1…    $    2,…       $    2,…       (1…  
  g…                                                                            
  s…                                                                            
  R…                                                                            
  a…    $    1,…       $    1,…       19%    $    4,…       $    4,…       6%   
  d…                                                                            
  e…                                                                            
  A…                                                                            
  i…                                                                            
  r…    $     18       $    170       (8…    $    11…       $    485       NM   
  a…                                                                            
  d…                                                                            
  e…                                                                            
  S…                                                                            
  g…                                                                            
  a…    $    1,…       $    1,…       14%    $    4,…       $    3,…       13%  
  a…                                                                            
  e…                                                                            
  O…                                                                            
  (…    $    -34       $    -87       (6…    $    -1…       $    -2…       (3…  
  e…                                                                            
  n…                                                                            
  D…                                                                            
  e…                                                                            
  (…    $    2.…       $    2.…       3%     $    -2…       $    6.…       NM   
  p…                                                                            
  s…                                                                            
  S…                                                                            
  u…                                                                            
  in                                                                            
  n…                                                                            
  d…         1,…            1,…       —%          1,…            1,…       (1…  
  e…                                                                            
  (…                                                                            
  p…                                                                            
  s…                                                                            
  c…                                                                            
  P…                                  165                                  121  
  g…         88…  %         86…  %    bps         87…  %         86…  %    bps  
  m…                                                                            
  R…                                                                            
  a…                                                                            
  d…                                                                            
  e…                                  200                                  (1…  
  as         19…  %         17…  %    bps         19…  %         19…  %    bps  
  a                                                                             
  %                                                                             
  of                                                                            
  r…                                                                            
  S…                                                                            
  g…                                                                            
  a…                                                                            
  a…                                                                            
  e…         18…  %         17…  %    115         19…  %         18…  %    91   
  as                                  bps                                  bps  
  a                                                                             
  %                                                                             
  of                                                                            
  r…                                                                            
  O…         50…  %         50…  %    (2…         0.5  %         47…  %    NM   
  m…                                  bps                                       
  E…                                  149                                       
  t…         19…  %         17…  %    bps         -4…  %         17…  %    NM   
  r…                                                                            
                                                                                
________________________________

NM - Not Meaningful

(1) Refer to Non-GAAP Financial Information section above for further
disclosures on non-GAAP financial measures. A reconciliation between GAAP and
non-GAAP financial information is provided in the tables below.
                          
  October 29, 2026    10  
 ──────────────────────── 
                          
                                                                                
                             GILEAD SCIENCES, INC.                              
                                                                                
                                                                                
            RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION            
                                                                                
                                  (unaudited)                                   
                                                                                
  (in                                                                           
  mil…                                                                          
  exc…                                                                          
  per…                                                                          
  and                                                                           
  per                                                                           
  sha…                                                                          
  amo…    Three                                Nine                             
  Cost    Mont…                                Mon…                             
  of      Ended                                End…                             
  goo…    Sept…                                Sep…                             
  sold    30,                                  30,                              
  rec…    2026               2025              2026              2025           
 ────────────────────────────────────────────────────────────────────────────── 
  GAAP                                                                          
  cost                                                                          
  of      $      1,571       $     1,569       $     4,595       $     4,6…     
  goo…                                                                          
  sold                                                                          
  Acq…                                                                          
  –               -587              -577             -1,7…             -1,…     
  amo…                                                                          
  Res…              -1                 —                -1                —     
  Non…                                                                          
  cost                                                                          
  of      $        983       $       992       $     2,851       $     2,8…     
  goo…                                                                          
  sold                                                                          
  Pro…                                                                          
  gro…                                                                          
  mar…                                                                          
  rec…                                                                          
  GAAP                                                                          
  pro…            81.0  %           78.6  %           79.9  %          78.1  %  
  gro…                                                                          
  mar…                                                                          
  Acq…                                                                          
  –                7.1  %            7.9  %            7.6  %           8.3  %  
  amo…                                                                          
  Res…               —  %              —  %              —  %             —  %  
  Non…                                                                          
  pro…            88.1  %           86.5  %           87.5  %          86.3  %  
  gro…                                                                          
  mar…                                                                          
  Res…                                                                          
  and                                                                           
  dev…                                                                          
  exp…                                                                          
  rec…                                                                          
  GAAP                                                                          
  res…                                                                          
  and     $      1,608       $     1,346       $     4,744       $     4,2…     
  dev…                                                                          
  exp…                                                                          
  Acq…                                                                          
  –                 -8                -4              -344              -41     
  oth…                                                                          
  cos…                                                                          
  Res…              -8                -8               -25              -52     
  Non…                                                                          
  res…                                                                          
  and     $      1,591       $     1,334       $     4,375       $     4,1…     
  dev…                                                                          
  exp…                                                                          
  IPR…                                                                          
  imp…                                                                          
  rec…                                                                          
  GAAP                                                                          
  IPR…    $          —       $         —       $     1,750       $      190     
  imp…                                                                          
  IPR…               —                 —             -1,7…             -190     
  imp…                                                                          
  Non…                                                                          
  IPR…    $          —       $         —       $         —       $        —     
  imp…                                                                          
  Sel…                                                                          
  gen…                                                                          
  and                                                                           
  adm…                                                                          
  exp…                                                                          
  rec…                                                                          
                                                                                
  GAAP                                                                          
  sel…                                                                          
  gen…    $      1,641       $     1,357       $     5,013       $     3,9…     
  and                                                                           
  adm…                                                                          
  exp…                                                                          
  Acq…                                                                          
  –                -69                 —              -454                —     
  oth…                                                                          
  cos…                                                                          
  Res…             -33                -5               -73              -49     
  Oth…               —                 —               -63                —     
  Non…                                                                          
  sel…                                                                          
  gen…    $      1,539       $     1,351       $     4,423       $     3,9…     
  and                                                                           
  adm…                                                                          
  exp…                                                                          
  Ope…                                                                          
  inc…                                                                          
  (lo…                                                                          
  rec…                                                                          
  GAAP                                                                          
  ope…    $      3,462       $     3,327       $     -4,3…       $     8,0…     
  inc…                                                                          
  (lo…                                                                          
  Acq…                                                                          
  –                587               577             1,742             1,7…     
  amo…                                                                          
  Acq…                                                                          
  –                 77                 4               798               41     
  oth…                                                                          
  cos…                                                                          
  Res…              42                14                99              101     
  IPR…               —                 —             1,750              190     
  imp…                                                                          
  Oth…               —                 —                63                —     
  Non…                                                                          
  ope…    $      4,168       $     3,921       $       107       $     10,…     
  inc…                                                                          
  Ope…                                                                          
  mar…                                                                          
  rec…                                                                          
  GAAP                                                                          
  ope…            41.7  %           42.8  %          -18.8  %          37.4  %  
  mar…                                                                          
  Acq…                                                                          
  –                7.1  %            7.4  %            7.6  %           8.1  %  
  amo…                                                                          
  Acq…                                                                          
  –                0.9  %              —  %            3.5  %           0.2  %  
  oth…                                                                          
  cos…                                                                          
  Res…             0.5  %            0.2  %            0.4  %           0.5  %  
  IPR…               —  %              —  %            7.6  %           0.9  %  
  imp…                                                                          
  Oth…               —  %              —  %            0.3  %             —  %  
  Non…                                                                          
  ope…            50.2  %           50.5  %            0.5  %          47.0  %  
  mar…                                                                          
  Oth…                                                                          
  (in…                                                                          
  exp…                                                                          
  net                                                                           
  rec…                                                                          
                                                                                
  GAAP                                                                          
  oth…                                                                          
  (in…    $        130       $      -569       $      -492       $     -449     
  exp…                                                                          
  net                                                                           
  (Lo…                                                                          
  gain                                                                          
  from            -164               483               321              198     
  equ…                                                                          
  sec…                                                                          
  net                                                                           
  Non…                                                                          
  oth…                                                                          
  (in…    $        -34       $       -87       $      -171       $     -251     
  exp…                                                                          
  net                                                                           
                                                                                
                          
  October 29, 2026    11  
 ──────────────────────── 
                          
                                                                                
                             GILEAD SCIENCES, INC.                              
                                                                                
     RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION - (Continued)     
                                                                                
                                  (unaudited)                                   
                                                                                
  (in                                                                           
  mil…                                                                          
  exc…                                                                          
  per…                                                                          
  and                                                                           
  per                                                                           
  sha…                                                                          
  amo…                                                                          
  Inc…    Three                                Nine                             
  (lo…    Mont…                                Mon…                             
  bef…    Ended                                End…                             
  inc…    Sept…                                Sep…                             
  tax…    30,                                  30,                              
  rec…    2026               2025              2026              2025           
 ────────────────────────────────────────────────────────────────────────────── 
  GAAP                                                                          
  inc…                                                                          
  (lo…    $      3,063       $     3,641       $     -4,6…       $     7,7…     
  bef…                                                                          
  inc…                                                                          
  tax…                                                                          
  Acq…                                                                          
  –                587               577             1,742             1,7…     
  amo…                                                                          
  Acq…                                                                          
  –                 77                 4               798               41     
  oth…                                                                          
  cos…                                                                          
  Res…              42                14                99              101     
  IPR…               —                 —             1,750              190     
  imp…                                                                          
  Loss                                                                          
  (ga…                                                                          
  from             164              -483              -321             -198     
  equ…                                                                          
  sec…                                                                          
  net                                                                           
  Oth…               —                 —                63                —     
  Non…                                                                          
  inc…                                                                          
  (lo…    $      3,933       $     3,752       $      -479       $     9,5…     
  bef…                                                                          
  inc…                                                                          
  tax…                                                                          
  Inc…                                                                          
  tax                                                                           
  exp…                                                                          
  rec…                                                                          
  GAAP                                                                          
  inc…    $        634       $       589       $     1,435       $     1,3…     
  tax                                                                           
  exp…                                                                          
  Inc…                                                                          
  tax                                                                           
  eff…                                                                          
  of                                                                            
  non…                                                                          
  adj…                                                                          
  Acq…                                                                          
  –                121               120               357              360     
  amo…                                                                          
  Acq…                                                                          
  –                 16                 —                95                —     
  oth…                                                                          
  cos…                                                                          
  Res…               9                 3                18               18     
  IPR…               —                 —               415               51     
  imp…                                                                          
  Loss                                                                          
  (ga…                                                                          
  from              30               -43               -78              -33     
  equ…                                                                          
  sec…                                                                          
  net                                                                           
  Dis…                                                                          
  and                                                                           
  rel…             -62               -11               -64             -101     
  tax                                                                           
  cha…                                                                          
  Non…                                                                          
  inc…    $        747       $       657       $     2,177       $     1,6…     
  tax                                                                           
  exp…                                                                          
  Eff…                                                                          
  tax                                                                           
  rate                                                                          
  rec…                                                                          
  GAAP                                                                          
  eff…            20.7  %           16.2  %          -31.1  %          18.0  %  
  tax                                                                           
  rate                                                                          
  Inc…                                                                          
  tax                                                                           
  eff…                                                                          
  of                                                                            
  abo…                                                                          
  non…                                                                          
  adj…            -1.7  %            1.3  %          -423…  %          -0.4  %  
  and                                                                           
  dis…                                                                          
  and                                                                           
  rel…                                                                          
  tax                                                                           
  adj…                                                                          
  Non…                                                                          
  eff…            19.0  %           17.5  %          -455…  %          17.6  %  
  tax                                                                           
  rate                                                                          
  Net                                                                           
  inc…                                                                          
  (lo…                                                                          
  rec…                                                                          
  GAAP                                                                          
  net     $      2,429       $     3,052       $     -6,0…       $     6,3…     
  inc…                                                                          
  (lo…                                                                          
  Acq…                                                                          
  –                467               457             1,385             1,3…     
  amo…                                                                          
  Acq…                                                                          
  –                 61                 4               703               41     
  oth…                                                                          
  cos…                                                                          
  Res…              33                11                81               83     
  IPR…               —                 —             1,335              139     
  imp…                                                                          
  Loss                                                                          
  (ga…                                                                          
  from             134              -440              -243             -165     
  equ…                                                                          
  sec…                                                                          
  net                                                                           
  Dis…                                                                          
  and                                                                           
  rel…              62                11                64              101     
  tax                                                                           
  cha…                                                                          
  Oth…               —                 —                63                —     
  Non…                                                                          
  net     $      3,186       $     3,095       $     -2,6…       $     7,9…     
  inc…                                                                          
  (lo…                                                                          
  Dil…                                                                          
  ear…                                                                          
  (lo…                                                                          
  per                                                                           
  sha…                                                                          
  rec…                                                                          
  GAAP                                                                          
  dil…                                                                          
  ear…    $       1.94       $      2.43       $     -4.87       $     5.04     
  (lo…                                                                          
  per                                                                           
  sha…                                                                          
  Acq…                                                                          
  –               0.37              0.36              1.11             1.09     
  amo…                                                                          
  Acq…                                                                          
  –               0.05                 —              0.57             0.03     
  oth…                                                                          
  cos…                                                                          
  Res…            0.03              0.01              0.07             0.07     
  IPR…               —                 —              1.07             0.11     
  imp…                                                                          
  Loss                                                                          
  (ga…                                                                          
  from            0.11             -0.35             -0.20             -0.…     
  equ…                                                                          
  sec…                                                                          
  net                                                                           
  Dis…                                                                          
  and                                                                           
  rel…            0.05              0.01              0.05             0.08     
  tax                                                                           
  cha…                                                                          
  Oth…               —                 —              0.05                —     
  Non…                                                                          
  dil…                                                                          
  ear…    $       2.55       $      2.47       $     -2.14       $     6.29     
  (lo…                                                                          
  per                                                                           
  sha…                                                                          
                                                                                
                          
  October 29, 2026    12  
 ──────────────────────── 
                          
                                                                                
                             GILEAD SCIENCES, INC.                              
                                                                                
     RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION - (Continued)     
                                                                                
                                  (unaudited)                                   
                                                                                
  (in                                                                           
  million…                                                                      
  except                                                                        
  percent…                                                                      
  and per     Three                            Nine                             
  share       Months                           Months                           
  amounts)    Ended                            Ended                            
  Non-GAAP    September                        September                        
  adjustm…    30,                              30,                              
  summary:    2026               2025          2026                2025         
 ────────────────────────────────────────────────────────────────────────────── 
  Cost of                                                                       
  goods       $           588    $      577    $          1,744    $     1,735  
  sold                                                                          
  adjustm…                                                                      
  Research                                                                      
  and                                                                           
  develop…                 16            12                 369             93  
  expenses                                                                      
  adjustm…                                                                      
  IPR&D                                                                         
  impairm…                  —             —               1,750            190  
  adjustm…                                                                      
  Selling,                                                                      
  general                                                                       
  and                     102             5                 590             49  
  adminis…                                                                      
  expenses                                                                      
  adjustm…                                                                      
  Total                                                                         
  non-GAAP                                                                      
  adjustm…                706           594               4,453          2,067  
  to costs                                                                      
  and                                                                           
  expenses                                                                      
  Other                                                                         
  (income)                                                                      
  expense,                164          -483                -321           -198  
  net,                                                                          
  adjustm…                                                                      
  Total                                                                         
  non-GAAP                                                                      
  adjustm…                870           112               4,132          1,868  
  before                                                                        
  income                                                                        
  taxes                                                                         
  Income                                                                        
  tax                                                                           
  effect                                                                        
  of                     -175           -79                -807           -396  
  non-GAAP                                                                      
  adjustm…                                                                      
  above                                                                         
  Discrete                                                                      
  and                                                                           
  related                  62            11                  64            101  
  tax                                                                           
  charges…                                                                      
  Total                                                                         
  non-GAAP                                                                      
  adjustm…    $           757    $       43    $          3,389    $     1,573  
  to net                                                                        
  income                                                                        
                                                                                
________________________________

(1) Relates to amortization of acquired intangibles.

(2) Adjustments include integration expenses and contingent consideration fair
value adjustments associated with Gilead’s recent acquisitions.

(3) Adjustments include donations of equity securities to the Gilead Foundation,
a California nonprofit organization, during the first quarter of 2026.

(4) Represents discrete and related deferred tax charges or benefits primarily
associated with acquisition-related adjustments and transfers of intangible
assets from a foreign subsidiary to Ireland and the United States.
                          
  October 29, 2026    13  
 ──────────────────────── 
                          
                                                                                
                             GILEAD SCIENCES, INC.                              
                                                                                
         RECONCILIATION OF GAAP TO NON-GAAP 2026 FULL-YEAR GUIDANCE (1)         
                                                                                
                                  (unaudited)                                   
                                                                                
  (in                                                                           
  millions,                                                                     
  except                                                                        
  percentages                                                                   
  and per        Provided        Updated May     Updated          Updated       
  share          February 10,    7,              August 4,        October       
  amounts)       2026            2026            2026             29, 2026      
 ────────────────────────────────────────────────────────────────────────────── 
  Projected                                                                     
  product                                                                       
  gross                                                                         
  margin GAAP                                                                   
  to                                                                            
  non-GAAP                                                                      
  reconcilia…                                                                   
  GAAP                                                                          
  projected                                                                     
  product        ~ 79.0%         ~ 79.0%         ~ 79.0%          ~ 79.0%       
  gross                                                                         
  margin                                                                        
  Acquisitio…    ~ 8.0%          ~ 8.0%          ~ 8.0%           ~ 8.0%        
  expenses                                                                      
  Non-GAAP                                                                      
  projected                                                                     
  product        ~ 87.0%         ~ 87.0%         ~ 87.0%          ~ 87.0%       
  gross                                                                         
  margin                                                                        
  Projected                                                                     
  operating                                                                     
  income                                                                        
  (loss) GAAP                                                                   
  to non-GAAP                                                                   
  reconcilia…                                                                   
  GAAP                                                                          
  projected      $11,400 -       $(1,000) -      $(2,250) -       $(3,150) -    
  operating      $11,900         $(500)          $(1,850)         $(2,750)      
  income                                                                        
  (loss)                                                                        
  Acquisitio…                                                                   
  IPR&D                                                                         
  impairment,    ~ 2,400         ~ 3,400         ~ 5,150          ~ 5,150       
  restructur…                                                                   
  and other                                                                     
  expenses                                                                      
  Non-GAAP                                                                      
  projected      $13,800 -       $2,400 -        $2,900 -         $2,000 -      
  operating      $14,300         $2,900          $3,300           $2,400        
  income                                                                        
  Projected                                                                     
  effective                                                                     
  tax rate                                                                      
  GAAP to                                                                       
  non-GAAP                                                                      
  reconcilia…                                                                   
  GAAP                                                                          
  projected      ~ 21%           ~ (150%) -      ~ (80%) -        ~ (50%) -     
  effective                      (220%)          (90%)            (55%)         
  tax rate                                                                      
  Income tax                                                                    
  effect of                                                                     
  above                                                                         
  non-GAAP                                                                      
  adjustments                                                                   
  and fair                                                                      
  value                                                                         
  adjustments    -~ 1%           NM              NM               NM            
  of equity                                                                     
  securities,                                                                   
  and                                                                           
  discrete                                                                      
  and                                                                           
  related tax                                                                   
  adjustments                                                                   
  Non-GAAP                                                                      
  projected      ~ 20%           ~ 190% -        ~ 140% - 115%    ~ 220% -      
  effective                      140%                             165%          
  tax rate                                                                      
  Projected                                                                     
  diluted                                                                       
  earnings                                                                      
  (loss) per                                                                    
  share GAAP                                                                    
  to non-GAAP                                                                   
  reconcilia…                                                                   
  GAAP                                                                          
  projected                                                                     
  diluted        $6.75 -         $(3.25) -       $(3.75) -        $(4.40) -     
  earnings       $7.15           $(2.85)         $(3.40)          $(4.05)       
  (loss)                                                                        
  per share                                                                     
  Acquisitio…                                                                   
  IPR&D                                                                         
  impairment,                                                                   
  restructur…                                                                   
  and other                                                                     
  expenses,                                                                     
  fair                                                                          
  value          ~ 1.70          ~ 2.20          ~ 3.10           ~ 3.20        
  adjustments                                                                   
  of equity                                                                     
  securities                                                                    
  and                                                                           
  discrete                                                                      
  and related                                                                   
  tax                                                                           
  adjustments                                                                   
  Non-GAAP                                                                      
  projected                                                                     
  diluted        $8.45 -         $(1.05) -       $(0.65) -        $(1.20) -     
  earnings       $8.85           $(0.65)         $(0.30)          $(0.85)       
  (loss) per                                                                    
  share                                                                         
                                                                                
________________________________

NM - Not Meaningful

(1) Our full-year guidance excludes the potential impact of any (i) acquisitions
or business development transactions that have not been executed, (ii) future
fair value adjustments of equity securities and (iii) discrete tax charges or
benefits associated with changes in tax related laws and guidelines that have
not been enacted, as Gilead is unable to project such amounts. The non-GAAP
full-year guidance includes non-GAAP adjustments to actual current period
results as well as adjustments for the known future impact associated with
events that have already occurred, such as future amortization of our intangible
assets and the future impact of discrete and related deferred tax charges or
benefits primarily associated with transfers of intangible assets from a foreign
subsidiary to Ireland and the United States.

(2) The GAAP and non-GAAP projected effective tax rates for the October 29, 2026
update include the impact of Acquired IPR&D expenses related to the acquisitions
of Arcellx, Tubulis and Ouro Medicines, which are not deductible for tax
purposes. Without these Acquired IPR&D expenses, the GAAP and non-GAAP projected
effective tax rate for FY26 would be ~21% and ~20%, respectively.
                          
  October 29, 2026    14  
 ──────────────────────── 
                          
                                                                                
                             GILEAD SCIENCES, INC.                              
                                                                                
                                                                                
                     CONDENSED CONSOLIDATED BALANCE SHEETS                      
                                                                                
                                  (unaudited)                                   
                                                                                
  (in millions)                  September 30,            December 31,          
  Assets                         2026                     2025                  
 ────────────────────────────────────────────────────────────────────────────── 
  Cash, cash equivalents and                                                    
  marketable                     $               6,437    $             10,605  
  debt securities                                                               
  Accounts receivable, net                       5,007                   4,913  
  Inventories(1)                                 4,424                   4,368  
  Property, plant and                            5,945                   5,606  
  equipment, net                                                                
  Intangible assets, net                        13,424                  16,978  
  Goodwill                                       8,314                   8,314  
  Other assets                                   7,858                   8,239  
  Total assets                   $              51,408    $             59,023  
  Liabilities and                                                               
  Stockholders’ Equity                                                          
  Current liabilities            $              12,002    $             11,813  
  Long-term liabilities                         26,451                  24,592  
  Stockholders’ equity(2)                       12,955                  22,618  
  Total liabilities and                                                         
  stockholders’                  $              51,408    $             59,023  
  equity                                                                        
                                                                                
________________________________

(1) Includes current and long-term inventories, which are disclosed separately
in the notes to our financial statements in Form 10-K and Form 10-Q.

(2) As of September 30, 2026 and December 31, 2025, there were 1,241 of shares
of common stock issued and outstanding.
                          
  October 29, 2026    15  
 ──────────────────────── 
                          
                                                                                
                             GILEAD SCIENCES, INC.                              
                                                                                
                                                                                
                         SELECTED CASH FLOW INFORMATION                         
                                                                                
                                  (unaudited)                                   
                                                                                
            Three                              Nine                             
            Months                             Months                           
  (in       Ended    Septe…                    Ended    Septe…                  
  milli…    2026        30,    2025            2026        30,    2025          
 ────────────────────────────────────────────────────────────────────────────── 
  Net                                                                           
  cash                                                                          
  provi…    $         5,035    $      4,109    $        11,152    $      6,692  
  by                                                                            
  opera…                                                                        
  activ…                                                                        
  Net                                                                           
  cash                                                                          
  used                 -244            -427             -8,821          -2,958  
  in                                                                            
  inves…                                                                        
  activ…                                                                        
  Net                                                                           
  cash                                                                          
  used               -1,528          -1,490             -3,423          -6,482  
  in                                                                            
  finan…                                                                        
  activ…                                                                        
  Effect                                                                        
  of                                                                            
  excha…                                                                        
  rate                                                                          
  chang…                 -4              -5                -34              87  
  on                                                                            
  cash                                                                          
  and                                                                           
  cash                                                                          
  equiv…                                                                        
  Net                                                                           
  change                                                                        
  in                                                                            
  cash                3,259           2,187             -1,126          -2,661  
  and                                                                           
  cash                                                                          
  equiv…                                                                        
  Cash                                                                          
  and                                                                           
  cash                                                                          
  equiv…              3,179           5,144              7,564           9,991  
  at                                                                            
  begin…                                                                        
  of                                                                            
  period                                                                        
  Cash                                                                          
  and                                                                           
  cash                                                                          
  equiv…    $         6,437    $      7,330    $         6,437    $      7,330  
  at end                                                                        
  of                                                                            
  period                                                                        
                                                                                
                                                                                
            Three                              Nine                             
            Months                             Months                           
  (in       Ended    Septem…                   Ended    Septem…                 
  milli…    2026         30,    2025           2026         30,    2025         
 ────────────────────────────────────────────────────────────────────────────── 
  Net                                                                           
  cash                                                                          
  provi…    $          5,035    $     4,109    $         11,152    $     6,692  
  by                                                                            
  opera…                                                                        
  activ…                                                                        
  Purch…                                                                        
  of                                                                            
  prope…                -237           -147                -494           -358  
  plant                                                                         
  and                                                                           
  equip…                                                                        
  Free                                                                          
  cash      $          4,798    $     3,962    $         10,657    $     6,335  
  flow(…                                                                        
                                                                                
________________________________

(1) Free cash flow is a non-GAAP liquidity measure. Please refer to our
disclosures in the Non-GAAP Financial Information section above.
                          
  October 29, 2026    16  
 ──────────────────────── 
                          
                                                                                
                             GILEAD SCIENCES, INC.                              
                                                                                
                                                                                
                             PRODUCT SALES SUMMARY                              
                                                                                
                                  (unaudited)                                   
                                                                                
                   Three                          Nine                          
                   Mont…                          Mont…                         
                   Ended                          Ended                         
  (in              Sept…                          Sept…                         
  mil…             30,                            30,                           
  HIV              2026            2025           2026             2025         
 ────────────────────────────────────────────────────────────────────────────── 
  Bik…    U.S.     $      3,284    $     2,940    $       8,837    $     8,212  
          Euro…             442            427            1,347          1,231  
          Rest                                                                  
          of                333            320            1,009            922  
          World                                                                 
                          4,059          3,686           11,193          10,3…  
  Des…    U.S.              998            652            2,680          1,791  
          Euro…              22             23               69             67  
          Rest                                                                  
          of                 26             25               71             81  
          World                                                                 
                          1,046            701            2,820          1,939  
  Gen…    U.S.              301            323              752            950  
          Euro…              27             34               97            114  
          Rest                                                                  
          of                 12             19               44             54  
          World                                                                 
                            339            377              892          1,118  
  Ode…    U.S.              226            206              550            642  
          Euro…              52             61              170            184  
          Rest                                                                  
          of                  8             10               27             30  
          World                                                                 
                            286            277              747            857  
  Sym…                                                                          
  -       U.S.              103             95              315            265  
  Rev…                                                                          
  sha…                                                                          
          Euro…              26             26               85             88  
          Rest                                                                  
          of                  3              3                8              9  
          World                                                                 
                            132            124              407            362  
  Yez…    U.S.              294             39              676             54  
          Euro…               —              —                —              —  
          Rest                                                                  
          of                 10              —               26              —  
          World                                                                 
                            305             39              702             54  
  Oth…    U.S.               55             43              114            144  
  HIV…                                                                          
          Euro…              22             22               72             85  
          Rest                                                                  
          of                  5              8               24             28  
          World                                                                 
                             82             73              211            256  
  Tot…    U.S.            5,261          4,299           13,924          12,0…  
  HIV                                                                           
          Euro…             591            592            1,839          1,769  
          Rest                                                                  
          of                397            386            1,209          1,124  
          World                                                                 
                          6,249          5,277           16,972          14,9…  
                                                                                
                          
  October 29, 2026    17  
 ──────────────────────── 
                          
                                                                                
                             GILEAD SCIENCES, INC.                              
                                                                                
                                                                                
                      PRODUCT SALES SUMMARY - (Continued)                       
                                                                                
                                  (unaudited)                                   
                                                                                
                       Three                        Nine                        
                      Months                      Months                        
                       Ended                       Ended                        
                     Septem…                      Septe…                        
                         30,                         30,                        
  (in                   2026         2025           2026           2025         
  mill…                                                                         
  Liver                                                                         
  Dise…                                                                         
  Livd…    U.S.               176           93              437            207  
           Europe              26           11               65             16  
           Rest                                                                 
           of                   1            —                1              —  
           World                                                                
                              203          105              503            223  
  Sofo…                                                                         
  /        U.S.               139          146              422            497  
  Velp…                                                                         
           Europe              59           65              200            227  
           Rest                                                                 
           of                  76           97              237            273  
           World                                                                
                              274          309              860            996  
  Veml…    U.S.               170          136              385            358  
           Europe              13           12               40             36  
           Rest                                                                 
           of                 151          132              435            389  
           World                                                                
                              333          280              860            783  
  Other                                                                         
  Liver    U.S.                39           39               74            100  
  Dise…                                                                         
           Europe              62           70              219            218  
           Rest                                                                 
           of                  16           17               56             52  
           World                                                                
                              117          126              349            370  
  Total                                                                         
  Liver    U.S.               524          414            1,319          1,162  
  Dise…                                                                         
           Europe             161          158              523            496  
           Rest                                                                 
           of                 243          247              729            714  
           World                                                                
                              927          819            2,571          2,372  
  Vekl…                                                                         
  Vekl…    U.S.                63          140              188            390  
           Europe              12           43               28             84  
           Rest                                                                 
           of                  11           93               36            225  
           World                                                                
                               86          277              253            700  
  Onco…                                                                         
  Cell                                                                          
  Ther…                                                                         
  Teca…    U.S.                24           40               83            122  
           Europe              31           35              102            107  
           Rest                                                                 
           of                   5            8               21             25  
           World                                                                
                               60           83              206            254  
  Yesc…    U.S.               114          123              366            444  
           Europe             107          151              392            455  
           Rest                                                                 
           of                  73           75              215            228  
           World                                                                
                              294          349              973          1,127  
  Total                                                                         
  Cell     U.S.               139          163              450            566  
  Ther…                                                                         
           Europe             138          186              494            562  
           Rest                                                                 
           of                  78           83              235            253  
           World                                                                
                              355          432            1,179          1,381  
  Trod…                                                                         
  Trod…    U.S.               336          221              896            626  
           Europe              98           89              285            259  
           Rest                                                                 
           of                  71           47              183            128  
           World                                                                
                              506          357            1,364          1,013  
  Total    U.S.               475          384            1,346          1,192  
  Onco…                                                                         
           Europe             236          275              779            821  
           Rest                                                                 
           of                 149          129              418            381  
           World                                                                
                              860          788            2,543          2,395  
                                                                                
                          
  October 29, 2026    18  
 ──────────────────────── 
                          
                                                                                
                             GILEAD SCIENCES, INC.                              
                                                                                
                                                                                
                      PRODUCT SALES SUMMARY - (Continued)                       
                                                                                
                                  (unaudited)                                   
                                                                                
                   Three                           Nine                         
                   Mont…                          Mont…                         
                   Ended                          Ended                         
                   Sept…                          Sept…                         
                     30,                            30,                         
  (in               2026           2025            2026            2025         
  mil…                                                                          
  Oth…                                                                          
  AmB…    U.S.                3              2               14             15  
          Euro…              52             69              158            201  
          Rest                                                                  
          of                 44             52              175            175  
          World                                                                 
                             99            123              347            391  
  Oth…    U.S.               36             34               97            125  
          Euro…               8              7               24             23  
          Rest                                                                  
          of                 25             20               57             55  
          World                                                                 
                             68             61              177            204  
  Tot…    U.S.               39             36              111            140  
  Oth…                                                                          
          Euro…              59             76              181            225  
          Rest                                                                  
          of                 69             72              232            230  
          World                                                                 
                            167            184              524            594  
  Tot…                                                                          
  pro…    U.S.            6,361          5,274           16,888          14,9…  
  sal…                                                                          
          Euro…           1,058          1,144            3,350          3,395  
          Rest                                                                  
          of                869            928            2,624          2,674  
          World                                                                 
                       $  8,289       $  7,345        $  22,862       $  21,0…  
                                                                                
________________________________

(1) Represents Gilead’s revenue from cobicistat (“C”), FTC and TAF in Symtuza
(darunavir/C/FTC/TAF), a fixed dose combination product commercialized by
Janssen Sciences Ireland Unlimited Company.

(2) Includes Atripla, Bixlenvo, Complera/Eviplera, Emtriva, Stribild, Sunlenca,
Truvada and Tybost.

(3) Includes Epclusa and the authorized generic version of Epclusa sold by
Gilead’s separate subsidiary, Asegua Therapeutics LLC (“Asegua”).

(4) Includes ledipasvir/sofosbuvir (Harvoni and the authorized generic version
of Harvoni sold by Asegua), Hepcludex, Sovaldi, Viread and Vosevi.

(5) Includes Cayston, Jyseleca, Letairis and Zydelig.

Sources

The 8-K item 2.02 filings (SEC EDGAR) and their EX-99 exhibits: the results release and, when filed, prepared remarks or the call transcript.

Also

Said vs did: the targets in these releases against what was then reported. Filings: every filing.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/GILD/export.csv") into a cell.

Next:Presentations
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.